{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:03:26Z","timestamp":1792706606324,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["This study was funded by Regione Campania under the PRE-SARC project, supported by Fondi di Rotazione ex L. 183\/1987, within the framework of the call \u201cMalattie Rare.\u201d"],"award-info":[{"award-number":["This study was funded by Regione Campania under the PRE-SARC project, supported by Fondi di Rotazione ex L. 183\/1987, within the framework of the call \u201cMalattie Rare.\u201d"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pazopanib, a multi-targeted tyrosine kinase inhibitor, is employed in the treatment of various malignancies, including metastatic non-adipocytic soft tissue sarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis adhered to PRISMA guidelines to evaluate the efficacy and toxicity of pazopanib monotherapy in treating sarcomas. A comprehensive search of PubMed\/MEDLINE and Scopus\/ELSEVIER databases was conducted, covering the period from 2009 to 2025. The included studies were evaluated for quality using the MINORS, Newcastle-Ottawa Scale, and RoB2 tools. The spectrum of toxicities and responses in sarcoma types was described. A meta-analysis was performed to compare the efficacy of pazopanib with non-placebo treatments, using both fixed-effect and random-effect models to calculate pooled hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 40 studies were included, encompassing a wide range of study designs and quality. The analysis revealed variable objective response rates (ORR) across different sarcoma types, with the highest ORRs by RECIST observed in desmoid tumors (37.0%) and alveolar soft part sarcoma (35.5%). Common toxicities included hypertension, liver function test abnormalities, and fatigue, with significant variability in dose reductions and treatment interruptions across studies. The pooled HRs for PFS and OS were 1.10 (95% CI: 0.69\u20131.25) and 0.99 (95% CI: 0.63\u20131.35), respectively, indicating no significant advantage of non-placebo treatments respect to pazopanib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pazopanib demonstrated histology-specific efficacy in sarcomas, with a manageable toxicity profile. Furthermore, it does not appear inferior to non-placebo interventions, highlighting the need for further comparative studies to clarify its role in the therapeutic landscape of advanced sarcomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-07775-1","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T17:23:28Z","timestamp":1770053008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A systematic review and meta-analysis of pazopanib efficacy and adverse effects in sarcomas"],"prefix":"10.1186","volume":"24","author":[{"given":"Fernanda","family":"Picozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-3855","authenticated-orcid":false,"given":"Alessandro","family":"Ottaiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Lucia","family":"Marretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Santorsola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pizzolorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina Della Vittoria","family":"Scarpati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bracigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"7775_CR1","doi-asserted-by":"publisher","first-page":"176484","DOI":"10.1016\/j.ejphar.2024.176484","volume":"970","author":"S Hussain","year":"2024","unstructured":"Hussain S, Mursal M, Verma G, Hasan SM, Khan MF. Targeting oncogenic kinases: insights on FDA approved tyrosine kinase inhibitors. Eur J Pharmacol. 2024;970:176484. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176484.","journal-title":"Eur J Pharmacol"},{"key":"7775_CR2","doi-asserted-by":"publisher","first-page":"9077926","DOI":"10.1155\/2024\/9077926","volume":"2024","author":"A Pathak","year":"2024","unstructured":"Pathak A, Pal AK, Roy S, Nandave M, Jain K. Role of angiogenesis and its biomarkers in development of targeted tumor therapies. Stem Cells Int. 2024;2024:9077926. https:\/\/doi.org\/10.1155\/2024\/9077926.","journal-title":"Stem Cells Int"},{"issue":"5","key":"7775_CR3","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1007\/s11030-022-10406-8","volume":"26","author":"P Shiri","year":"2022","unstructured":"Shiri P, Ramezanpour S, Amani AM, Dehaen W. A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy. Mol Divers. 2022;26(5):2981\u20133002. https:\/\/doi.org\/10.1007\/s11030-022-10406-8.","journal-title":"Mol Divers"},{"issue":"7","key":"7775_CR4","doi-asserted-by":"publisher","first-page":"103989","DOI":"10.1016\/j.drudis.2024.103989","volume":"29","author":"JY Ai","year":"2024","unstructured":"Ai JY, Liu CF, Zhang W, Rao GW. Current status of drugs targeting PDGF\/PDGFR. Drug Discov Today. 2024;29(7):103989. https:\/\/doi.org\/10.1016\/j.drudis.2024.103989.","journal-title":"Drug Discov Today"},{"issue":"11","key":"7775_CR5","doi-asserted-by":"publisher","first-page":"13131","DOI":"10.3390\/cimb46110783","volume":"46","author":"S Fan","year":"2024","unstructured":"Fan S, Chen Y, Wang W, Xu W, Tian M, Liu Y, Zhou Y, Liu D, Xia Q, Dong L. Pharmacological and biological targeting of FGFR1 in cancer. Curr Issues Mol Biol. 2024;46(11):13131\u201350. https:\/\/doi.org\/10.3390\/cimb46110783.","journal-title":"Curr Issues Mol Biol"},{"issue":"6","key":"7775_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.23.01275","volume":"42","author":"AR Weiss","year":"2024","unstructured":"Weiss AR, Harrison DJ. Soft tissue sarcomas in adolescents and young adults. J Clin Oncol. 2024;42(6):675\u201385. https:\/\/doi.org\/10.1200\/JCO.23.01275.","journal-title":"J Clin Oncol"},{"issue":"11","key":"7775_CR7","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De \u00c1lava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Kr\u00e1korov\u00e1 DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Sch\u00f6ffski P, Sleijfer S, Strauss D, Strauss S, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Casali PG, Stacchiotti S. ESMO guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.006.","journal-title":"Ann Oncol"},{"issue":"9829","key":"7775_CR8","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Sch\u00f6ffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P. EORTC soft tissue and bone sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(12)60651-5.","journal-title":"Lancet"},{"key":"7775_CR9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"9","key":"7775_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"issue":"9","key":"7775_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"key":"7775_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"4","key":"7775_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jspi.2009.09.017","volume":"140","author":"D Jackson","year":"2010","unstructured":"Jackson D, Bowden J, Baker R. How does the dersimonian and Laird procedure for random effects meta-analysis compare with its more efficient but harder to compute counterparts? J Stat Plann Inference. 2010;140(4):961\u201370. https:\/\/doi.org\/10.1016\/j.jspi.2009.09.017.","journal-title":"J Stat Plann Inference"},{"key":"7775_CR14","volume-title":"Statistics with confidence: confidence intervals and statistical guidelines","year":"2000","unstructured":"Altman DG, Bryant TN, Gardner MJ, Machin D, editors. Statistics with confidence: confidence intervals and statistical guidelines. 2nd ed. UK: Br Med J; 2000.","edition":"2"},{"issue":"7414","key":"7775_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"7109","key":"7775_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"19","key":"7775_CR17","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Sch\u00f6ffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126\u201332. https:\/\/doi.org\/10.1200\/JCO.2008.21.3223.","journal-title":"J Clin Oncol"},{"key":"7775_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12885-015-1160-x","volume":"15","author":"KH Yoo","year":"2015","unstructured":"Yoo KH, Kim HS, Lee SJ, Park SH, Kim SJ, Kim SH, La Choi Y, Shin KH, Cho YJ, Lee J, Rha SY. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer. 2015;15:154. https:\/\/doi.org\/10.1186\/s12885-015-1160-x.","journal-title":"BMC Cancer"},{"key":"7775_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13569-015-0022-2","volume":"5","author":"M Maruzzo","year":"2015","unstructured":"Maruzzo M, Martin-Liberal J, Messiou C, Miah A, Thway K, Alvarado R, Judson I, Benson C. Pazopanib as first line treatment for solitary fibrous tumours: the Royal marsden hospital experience. Clin Sarcoma Res. 2015;5:5. https:\/\/doi.org\/10.1186\/s13569-015-0022-2.","journal-title":"Clin Sarcoma Res"},{"issue":"9","key":"7775_CR20","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/cncr.29961","volume":"122","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Matsumine A, Kawai A, Araki N, Goto T, Yonemoto T, Sugiura H, Nishida Y, Hiraga H, Honoki K, Yasuda T, Boku S, Sudo A, Ueda T. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese musculoskeletal oncology group (JMOG) study. Cancer. 2016;122(9):1408\u201316. https:\/\/doi.org\/10.1002\/cncr.29961.","journal-title":"Cancer"},{"issue":"1","key":"7775_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","volume":"56","author":"A Koll\u00e1r","year":"2017","unstructured":"Koll\u00e1r A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Liti\u00e8re S, Marreaud S, Gronchi A, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC soft tissue and bone sarcoma group (STBSG) retrospective analysis. Acta Oncol. 2017;56(1):88\u201392. https:\/\/doi.org\/10.1080\/0284186X.2016.1234068.","journal-title":"Acta Oncol"},{"issue":"10","key":"7775_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-017-1030-2","volume":"34","author":"RL Jones","year":"2017","unstructured":"Jones RL, Katz D, Loggers ET, Davidson D, Rodler ET, Pollack SM. Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Med Oncol. 2017;34(10):167. https:\/\/doi.org\/10.1007\/s12032-017-1030-2.","journal-title":"Med Oncol"},{"issue":"1","key":"7775_CR23","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.3802\/jgo.2018.29.e3","volume":"29","author":"HJ Kim","year":"2018","unstructured":"Kim HJ, Kim Y, Lee SJ, Lee J, Park SH. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. J Gynecol Oncol. 2018;29(1):e3. https:\/\/doi.org\/10.3802\/jgo.2018.29.e3.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"7775_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1634\/theoncologist.2017-0161","volume":"23","author":"S Stacchiotti","year":"2018","unstructured":"Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A. Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist. 2018;23(1):62\u201370. https:\/\/doi.org\/10.1634\/theoncologist.2017-0161.","journal-title":"Oncologist"},{"issue":"9","key":"7775_CR25","doi-asserted-by":"publisher","first-page":"e180219","DOI":"10.1001\/jamaoncol.2018.0219","volume":"4","author":"AM Frezza","year":"2018","unstructured":"Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, Gemcitabine, and pazopanib in epithelioid sarcoma: A Multi-institutional case series. JAMA Oncol. 2018;4(9):e180219. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0219.","journal-title":"JAMA Oncol"},{"issue":"1","key":"7775_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.2018-0464","volume":"24","author":"M Kim","year":"2019","unstructured":"Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, Kim DW, Heo DS. A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma. Oncologist. 2019;24(1):20\u2013e29. https:\/\/doi.org\/10.1634\/theoncologist.2018-0464.","journal-title":"Oncologist"},{"key":"7775_CR27","unstructured":"Sunar V, Korkmaz V, Akin S, Can Guven D, Arik Z, Ates O, Yilmaz M, Mutlu Meydanli M, Oksuzoglu B. Efficacy of pazopanib in patients with metastatic uterine sarcoma: a multi-institutional study. J BUON. 2019;24(6):2327\u201332."},{"key":"7775_CR28","doi-asserted-by":"publisher","unstructured":"Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(9):1252\u20131262. doi: 10.1016\/S1470-2045(19)30319-5. Epub 2019 Jul 19. Erratum in: Lancet Oncol. 2019;20(10):e559. https:\/\/doi.org\/10.1016\/S1470-2045(19)30589-3","DOI":"10.1016\/S1470-2045(19)30589-3"},{"issue":"1","key":"7775_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","volume":"20","author":"J Martin-Broto","year":"2019","unstructured":"Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Pe\u00f1a-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Del Garcia X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(1):134\u201344. https:\/\/doi.org\/10.1016\/S1470-2045(18)30676-4.","journal-title":"Lancet Oncol"},{"issue":"9","key":"7775_CR30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S1470-2045(19)30276-1","volume":"20","author":"M Toulmonde","year":"2019","unstructured":"Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019;20(9):1263\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(19)30276-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"7775_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/medsci7030048","volume":"7","author":"T Seto","year":"2019","unstructured":"Seto T, Song MN, Trieu M, Yu J, Sidhu M, Liu CM, Sam D, Pan M. Real-World experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California. Med Sci (Basel). 2019;7(3):48. https:\/\/doi.org\/10.3390\/medsci7030048.","journal-title":"Med Sci (Basel)"},{"key":"7775_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.06.016","volume":"137","author":"AC Hirbe","year":"2020","unstructured":"Hirbe AC, Eulo V, Moon CI, Luo J, Myles S, Seetharam M, Toeniskoetter J, Kershner T, Haarberg S, Agulnik M, Monga V, Milhem M, Parkes A, Robinson S, Okuno S, Attia S, Van Tine BA. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer. 2020;137:1\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.016.","journal-title":"Eur J Cancer"},{"issue":"30","key":"7775_CR33","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1200\/JCO.20.00714","volume":"38","author":"V Gr\u00fcnwald","year":"2020","unstructured":"Gr\u00fcnwald V, Karch A, Schuler M, Sch\u00f6ffski P, Kopp HG, Bauer S, Kasper B, Lindner LH, Chemnitz JM, Crysandt M, Stein A, Steffen B, Richter S, Egerer G, Ivanyi P, Zimmermann S, Liu X, Kunitz A. Randomized comparison of pazopanib and doxorubicin as First-Line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German intergroup study. J Clin Oncol. 2020;38(30):3555\u201364. https:\/\/doi.org\/10.1200\/JCO.20.00714.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7775_CR34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S1470-2045(19)30826-5","volume":"21","author":"J Martin-Broto","year":"2020","unstructured":"Martin-Broto J, Cruz J, Penel N, Le Cesne A, Hindi N, Luna P, Moura DS, Bernabeu D, de Alava E, Lopez-Guerrero JA, Dopazo J, Pe\u00f1a-Chilet M, Gutierrez A, Collini P, Karanian M, Redondo A, Lopez-Pousa A, Grignani G, Diaz-Martin J, Marcilla D, Fernandez-Serra A, Gonzalez-Aguilera C, Casali PG, Blay JY, Stacchiotti S. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):456\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(19)30826-5.","journal-title":"Lancet Oncol"},{"issue":"2","key":"7775_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tranon.2019.12.001","volume":"13","author":"N Aggerholm-Pedersen","year":"2020","unstructured":"Aggerholm-Pedersen N, Rossen P, Rose H, Safwat A. Pazopanib in the treatment of bone sarcomas: clinical experience. Transl Oncol. 2020;13(2):295\u20139. https:\/\/doi.org\/10.1016\/j.tranon.2019.12.001.","journal-title":"Transl Oncol"},{"issue":"1","key":"7775_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/ijc.33201","volume":"148","author":"Y Nishida","year":"2021","unstructured":"Nishida Y, Urakawa H, Nakayama R, Kobayashi E, Ozaki T, Ae K, Matsumoto Y, Tsuchiya H, Goto T, Hiraga H, Naka N, Takahashi S, Ando Y, Ando M, Kuwatsuka Y, Hamada S, Ueda T, Kawai A. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors. Int J Cancer. 2021;148(1):140\u20139. https:\/\/doi.org\/10.1002\/ijc.33201.","journal-title":"Int J Cancer"},{"issue":"4","key":"7775_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11523-020-00731-z","volume":"15","author":"CR Oh","year":"2020","unstructured":"Oh CR, Hong JY, Kim JH, Lee JS, Kim HS, Kim TW, Ahn JH, Kim JE. Real-World outcomes of pazopanib treatment in Korean patients with advanced soft tissue sarcoma: A multicenter retrospective cohort study. Target Oncol. 2020;15(4):485\u201393. https:\/\/doi.org\/10.1007\/s11523-020-00731-z.","journal-title":"Target Oncol"},{"issue":"1","key":"7775_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/cncr.32515","volume":"126","author":"W Chow","year":"2020","unstructured":"Chow W, Frankel P, Ruel C, Araujo DM, Milhem M, Okuno S, Hartner L, Undevia S, Staddon A. Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma. Cancer. 2020;126(1):105\u201311. https:\/\/doi.org\/10.1002\/cncr.32515.","journal-title":"Cancer"},{"key":"7775_CR39","doi-asserted-by":"publisher","first-page":"100275","DOI":"10.1016\/j.ctarc.2020.100275","volume":"26","author":"NA Halim","year":"2021","unstructured":"Halim NA, Sayed RE, Alameh IA, Khoury J, Nakib CE, Zerdan MB, Charafeddine M, Farhat F, Karak FE, Assi HI. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region. Cancer Treat Res Commun. 2021;26:100275. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100275.","journal-title":"Cancer Treat Res Commun"},{"issue":"22","key":"7775_CR40","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.21037\/atm-20-6377","volume":"8","author":"J Liu","year":"2020","unstructured":"Liu J, Fan Z, Li S, Gao T, Xue R, Bai C, Zhang L, Tan Z, Fang Z. Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases. Ann Transl Med. 2020;8(22):1493. https:\/\/doi.org\/10.21037\/atm-20-6377. PMID: 33313238; PMCID: PMC7729354.","journal-title":"Ann Transl Med"},{"issue":"2","key":"7775_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaoncol.2020.6564","volume":"7","author":"HJ Schmoll","year":"2021","unstructured":"Schmoll HJ, Lindner LH, Reichardt P, Hei\u00dfner K, Kopp HG, Kessler T, Mayer-Steinacker R, R\u00fcssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A. Efficacy of pazopanib with or without gemcitabine in patients with Anthracycline- and\/or Ifosfamide-Refractory soft tissue sarcoma: final results of the PAPAGEMO phase 2 randomized clinical trial. JAMA Oncol. 2021;7(2):255\u201362. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6564.","journal-title":"JAMA Oncol"},{"key":"7775_CR42","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3332\/ecancer.2021.1281","volume":"15","author":"B Kataria","year":"2021","unstructured":"Kataria B, Sharma A, Biswas B, Bakhshi S, Pushpam D. Pazopanib in rare histologies of metastatic soft tissue sarcoma. Ecancermedicalscience. 2021;15:1281. https:\/\/doi.org\/10.3332\/ecancer.2021.1281.","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"7775_CR43","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.4143\/crt.2020.1337","volume":"53","author":"C Park","year":"2021","unstructured":"Park C, Kim M, Kwak Y, Moon KC, Kim SH, Keam B, Kim YJ, Kim TM, Kim DW. Real-World clinical outcomes and prognostic factors for patients with advanced angiosarcoma who received systemic treatment. Cancer Res Treat. 2021;53(4):1195\u2013203. https:\/\/doi.org\/10.4143\/crt.2020.1337.","journal-title":"Cancer Res Treat"},{"key":"7775_CR44","doi-asserted-by":"publisher","first-page":"6755","DOI":"10.2147\/CMAR.S323499","volume":"13","author":"B Alshamsan","year":"2021","unstructured":"Alshamsan B, Badran A, Alshibany A, Maraiki F, Elshenawy MA, Elhassan T, Atallah JP. Real-World outcome and prognostic factors of pazopanib in advanced soft tissue sarcoma. Cancer Manag Res. 2021;13:6755\u201366. https:\/\/doi.org\/10.2147\/CMAR.S323499.","journal-title":"Cancer Manag Res"},{"issue":"8","key":"7775_CR45","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/cam4.3807","volume":"10","author":"AM Frezza","year":"2021","unstructured":"Frezza AM, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TW, Teterycz P, Baldi GG, Italiano A, Penel N, Brunello A, Duffaud F, Hindi N, Iwata S, Smrke A, Fedenko A, Gelderblom H, Van Der Graaf W, Vozy A, Connolly E, Grassi M, Benjamin RS, Broto JM, Grignani G, Jones RL, Kawai A, Tysarowski A, Mariani L, Casali PG, Stacchiotti S. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the world sarcoma network and a review of literature. Cancer Med. 2021;10(8):2645\u201359. https:\/\/doi.org\/10.1002\/cam4.3807.","journal-title":"Cancer Med"},{"issue":"5","key":"7775_CR46","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jamaoncol.2021.3547","volume":"8","author":"RL Jones","year":"2022","unstructured":"Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: A randomized clinical trial. JAMA Oncol. 2022;8(5):740\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3547.","journal-title":"JAMA Oncol"},{"key":"7775_CR47","doi-asserted-by":"publisher","first-page":"3691025","DOI":"10.1155\/2022\/3691025","volume":"2022","author":"P Frankel","year":"2022","unstructured":"Frankel P, Ruel C, Uche A, Choy E, Okuno S, Somiah N, Chow WA. Pazopanib in patients with osteosarcoma metastatic to the lung: phase 2 study results and the lessons for tumor measurement. J Oncol. 2022;2022:3691025. https:\/\/doi.org\/10.1155\/2022\/3691025.","journal-title":"J Oncol"},{"issue":"19","key":"7775_CR48","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1002\/cncr.34403","volume":"128","author":"JA Thiebaud","year":"2022","unstructured":"Thiebaud JA, Ravi V, Litwin S, Schuetze SM, Movva S, Agulnik M, Kraft AS, Tetzlaff ED, Somaiah N, von Mehren M. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022;128(19):3516\u201322. https:\/\/doi.org\/10.1002\/cncr.34403.","journal-title":"Cancer"},{"issue":"1","key":"7775_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/cncr.32508","volume":"126","author":"AM Frezza","year":"2020","unstructured":"Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the world sarcoma network. Cancer. 2020;126(1):98\u2013104. https:\/\/doi.org\/10.1002\/cncr.32508.","journal-title":"Cancer"},{"issue":"2","key":"7775_CR50","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4143\/crt.2022.251","volume":"55","author":"JY Hong","year":"2023","unstructured":"Hong JY, Cho HJ, Yun KH, Lee YH, Kim SH, Baek W, Kim SK, Lee Y, Choi YL, Kwon M, Kim HS, Lee J. Comprehensive molecular characterization of soft tissue sarcoma for prediction of Pazopanib-Based treatment response. Cancer Res Treat. 2023;55(2):671\u201383. https:\/\/doi.org\/10.4143\/crt.2022.251.","journal-title":"Cancer Res Treat"},{"issue":"9","key":"7775_CR51","doi-asserted-by":"publisher","first-page":"103689","DOI":"10.1016\/j.esmoop.2024.103689","volume":"9","author":"C Giani","year":"2024","unstructured":"Giani C, Denu RA, Ljevar S, Gronchi A, Napolitano A, Rosenbaum E, Salawu A, Bajpai J, Connolly EA, Lee ATJ, Trent JC, Kose\u0142a-Paterczyk H, Chia-Chen Li Z, Ogura K, Palmerini E, Baldi GG, Brunello A, Campos F, Cicala CM, Maki RG, Wagner AJ, Andelkovic V, Loong HH, Wong DD, Jones RL, Tap WD, Taverna SM, Lazar AJ, Demicco EG, Hong A, Bovee JVMG, Dei Tos AP, Fletcher CDM, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, Stacchiotti S. Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare sarcoma working group. ESMO Open. 2024;9(9):103689. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103689.","journal-title":"ESMO Open"},{"issue":"12","key":"7775_CR52","doi-asserted-by":"publisher","first-page":"103995","DOI":"10.1016\/j.esmoop.2024.103995","volume":"9","author":"B Vincenzi","year":"2024","unstructured":"Vincenzi B, Olimpieri PP, Celant S, Mazzocca A, Cortellini A, Comandone A, Tomassini L, Di Segni S, Russo P, Casali PG. Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian National registry. ESMO Open. 2024;9(12):103995. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103995.","journal-title":"ESMO Open"},{"issue":"3","key":"7775_CR53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3892\/ol.2024.14848","volume":"29","author":"CM S\u00f6ylemez","year":"2024","unstructured":"S\u00f6ylemez CM, G\u00fcrsoy P, \u015eanli UA. Response rates of pazopanib therapy in metastatic soft tissue sarcoma using real\u2013world data. Oncol Lett. 2024;29(3):102. https:\/\/doi.org\/10.3892\/ol.2024.14848.","journal-title":"Oncol Lett"},{"issue":"4","key":"7775_CR54","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00432-025-06208-8","volume":"151","author":"A Burkhard-Meier","year":"2025","unstructured":"Burkhard-Meier A, Rechenauer VV, Jurinovic V, Albertsmeier M, Hoberger M, D\u00fcrr HR, Klein A, Kn\u00f6sel T, Kunz WG, Mock A, Pusztai A, V\u00f6lkl M, von Bergwelt-Baildon M, Lindner LH, Di Gioia D, Berclaz LM. First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysis. J Cancer Res Clin Oncol. 2025;151(4):150. https:\/\/doi.org\/10.1007\/s00432-025-06208-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7775_CR55","doi-asserted-by":"publisher","first-page":"1611965","DOI":"10.3389\/pore.2025.1611965","volume":"31","author":"N Ecker","year":"2025","unstructured":"Ecker N, Aranyi M, Kiss E, Kiss N, Lahm E, Nagy Z, Sikter M, Szab\u00f3 \u00c1, Szentesi AS, Tak\u00e1cs K, Uhlyarik A, Vachaja J, Seb\u0151k B, P\u00e1pai Z. Real-world experience with pazopanib in locally advanced and metastatic soft tissue sarcomas: a Hungarian retrospective single-center study. Pathol Oncol Res. 2025;31:1611965. https:\/\/doi.org\/10.3389\/pore.2025.1611965.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"7775_CR56","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejca.2014.11.008","volume":"51","author":"S Taieb","year":"2015","unstructured":"Taieb S, Saada-Bouzid E, Tresch E, Ryckewaert T, Bompas E, Italiano A, Guillemet C, Peugniez C, Piperno-Neumann S, Thyss A, Maynou C, Clisant S, Penel N, French Sarcoma Group. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. Eur J Cancer. 2015;51(2):202\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2014.11.008.","journal-title":"Eur J Cancer"},{"issue":"23","key":"7775_CR57","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1002\/cncr.27624","volume":"118","author":"S Stacchiotti","year":"2012","unstructured":"Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG, Gronchi A. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 2012;118(23):5857\u201366. https:\/\/doi.org\/10.1002\/cncr.27624.","journal-title":"Cancer"},{"issue":"9","key":"7775_CR58","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","volume":"56","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet. 2017;56(9):987\u201397. https:\/\/doi.org\/10.1007\/s40262-017-0510-z.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"7775_CR59","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1074248418769612","volume":"23","author":"CN Justice","year":"2018","unstructured":"Justice CN, Derbala MH, Baich TM, Kempton AN, Guo AS, Ho TH, Smith SA. The impact of pazopanib on the cardiovascular system. J Cardiovasc Pharmacol Ther. 2018;23(5):387\u201398. https:\/\/doi.org\/10.1177\/1074248418769612.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"7775_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/cancers16020350","volume":"16","author":"M Santorsola","year":"2024","unstructured":"Santorsola M, Capuozzo M, Nasti G, Sabbatino F, Di Mauro A, Di Mauro G, Vanni G, Maiolino P, Correra M, Granata V, Gualillo O, Berretta M, Ottaiano A. Exploring the spectrum of VEGF inhibitors\u2019 toxicities from systemic to Intra-Vitreal usage in medical practice. Cancers (Basel). 2024;16(2):350. https:\/\/doi.org\/10.3390\/cancers16020350.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"7775_CR61","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1200\/JCO.1993.11.7.1269","volume":"11","author":"JH Edmonson","year":"1993","unstructured":"Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR. Randomized comparison of doxorubicin alone versus Ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269\u201375. https:\/\/doi.org\/10.1200\/JCO.1993.11.7.1269.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7775_CR62","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1200\/JCO.1995.13.7.1537","volume":"13","author":"A Santoro","year":"1995","unstructured":"Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al. Doxorubicin versus CYVADIC versus doxorubicin plus Ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol. 1995;13(7):1537\u201345. https:\/\/doi.org\/10.1200\/JCO.1995.13.7.1537.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7775_CR63","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","volume":"13","author":"BA Nacev","year":"2022","unstructured":"Nacev BA, Sanchez-Vega F, Smith SA, Antonescu CR, Rosenbaum E, Shi H, Tang C, Socci ND, Rana S, Gularte-M\u00e9rida R, Zehir A, Gounder MM, Bowler TG, Luthra A, Jadeja B, Okada A, Strong JA, Stoller J, Chan JE, Chi P, D\u2019Angelo SP, Dickson MA, Kelly CM, Keohan ML, Movva S, Thornton K, Meyers PA, Wexler LH, Slotkin EK, Glade Bender JL, Shukla NN, Hensley ML, Healey JH, La Quaglia MP, Alektiar KM, Crago AM, Yoon SS, Untch BR, Chiang S, Agaram NP, Hameed MR, Berger MF, Solit DB, Schultz N, Ladanyi M, Singer S, Tap WD. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nat Commun. 2022;13(1):3405. https:\/\/doi.org\/10.1038\/s41467-022-30453-x.","journal-title":"Nat Commun"},{"issue":"1","key":"7775_CR64","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1038\/s41467-022-30496-0","volume":"13","author":"MM Gounder","year":"2022","unstructured":"Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, Krishnan A, Lee J, Attia S, Abida W, Drilon A, Chi P, Angelo SP, Dickson MA, Keohan ML, Kelly CM, Agulnik M, Chawla SP, Choy E, Chugh R, Meyer CF, Myer PA, Moore JL, Okimoto RA, Pollock RE, Ravi V, Singh AS, Somaiah N, Wagner AJ, Healey JH, Frampton GM, Venstrom JM, Ross JS, Ladanyi M, Singer S, Brennan MF, Schwartz GK, Lazar AJ, Thomas DM, Maki RG, Tap WD, Ali SM, Jin DX. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022;13(1):3406. https:\/\/doi.org\/10.1038\/s41467-022-30496-0.","journal-title":"Nat Commun"},{"issue":"10","key":"7775_CR65","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.3390\/cancers14102548","volume":"14","author":"J Vibert","year":"2022","unstructured":"Vibert J, Watson S. The molecular biology of soft tissue sarcomas: current knowledge and future perspectives. Cancers (Basel). 2022;14(10):2548. https:\/\/doi.org\/10.3390\/cancers14102548.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"7775_CR66","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/s41467-023-37049-z","volume":"14","author":"M Tanaka","year":"2023","unstructured":"Tanaka M, Chuaychob S, Homme M, Yamazaki Y, Lyu R, Yamashita K, Ae K, Matsumoto S, Kumegawa K, Maruyama R, Qu W, Miyagi Y, Yokokawa R, Nakamura T. ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma. Nat Commun. 2023;14(1):1957. https:\/\/doi.org\/10.1038\/s41467-023-37049-z.","journal-title":"Nat Commun"},{"issue":"1","key":"7775_CR67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/his.12311","volume":"64","author":"AP Dei Tos","year":"2014","unstructured":"Dei Tos AP. Liposarcomas: diagnostic pitfalls and new insights. Histopathology. 2014;64(1):38\u201352. https:\/\/doi.org\/10.1111\/his.12311.","journal-title":"Histopathology"},{"issue":"2","key":"7775_CR68","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.semradonc.2023.12.002","volume":"34","author":"A Ewongwo","year":"2024","unstructured":"Ewongwo A, Hui C, Moding EJ. Opportunity in complexity: Harnessing molecular biomarkers and liquid biopsies for personalized sarcoma care. Semin Radiat Oncol. 2024;34(2):195\u2013206. https:\/\/doi.org\/10.1016\/j.semradonc.2023.12.002.","journal-title":"Semin Radiat Oncol"},{"issue":"17","key":"7775_CR69","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.3390\/cancers14174186","volume":"14","author":"S Hidalgo-R\u00edos","year":"2022","unstructured":"Hidalgo-R\u00edos S, Carrillo-Garc\u00eda J, Moura DS, Stacchiotti S, L\u00f3pez-Pousa A, Redondo A, Italiano A, Guti\u00e9rrez A, Grignani G, Hindi N, L\u00f3pez-Guerrero JA, Muro XGD, Trufero JM, Palmerini E, Garc\u00eda AS, Bernabeu D, Le Cesne A, Casali PG, Blay JY, Cruz Jurado J, Martin-Broto J. Peripheral inflammatory indexes Neutrophil\/Lymphocyte ratio (NLR) and red cell distribution width (RDW) as prognostic biomarkers in advanced solitary fibrous tumour (SFT) treated with pazopanib. Cancers (Basel). 2022;14(17):4186. https:\/\/doi.org\/10.3390\/cancers14174186.","journal-title":"Cancers (Basel)"},{"key":"7775_CR70","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.2147\/CMAR.S191199","volume":"11","author":"C Mirili","year":"2019","unstructured":"Mirili C, Payda\u015f S, Guney IB, Ogul A, Gokcay S, Buyuksimsek M, Yetisir AE, Karaalioglu B, Tohumcuoglu M, Seydaoglu G. Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study. Cancer Manag Res. 2019;11:3445\u201353. https:\/\/doi.org\/10.2147\/CMAR.S191199.","journal-title":"Cancer Manag Res"},{"issue":"11","key":"7775_CR71","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1097\/CORR.0000000000001322","volume":"478","author":"Y Suehara","year":"2020","unstructured":"Suehara Y, Kohsaka S, Yamaguchi S, Hayashi T, Kurihara T, Sano K, Sasa K, Akaike K, Ueno T, Kojima S, Ikegami M, Mizuno S, Okubo T, Kim Y, Kaneko K, Saito T, Kato S, Mano H. Assessment of predictive biomarkers of the response to pazopanib based on an integrative analysis of High-grade Soft-tissue sarcomas: analysis of a tumor sample from a responder and patients with other Soft-tissue sarcomas. Clin Orthop Relat Res. 2020;478(11):2461\u201376. https:\/\/doi.org\/10.1097\/CORR.0000000000001322.","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"7775_CR72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3892\/mco.2024.2767","volume":"21","author":"H Matsuoka","year":"2024","unstructured":"Matsuoka H, Yoshida KI, Nakai S, Suzuki R, Imura Y, Takami H, Watanabe M, Wakamatsu T, Tamiya H, Outani H, Yagi T, Kakunaga S, Takenaka S. Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of PDGFRA, VEGFR2 and KIT: A case report. Mol Clin Oncol. 2024;21(4):69. https:\/\/doi.org\/10.3892\/mco.2024.2767.","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"7775_CR73","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CCO.0000000000000644","volume":"32","author":"P Sch\u00f6ffski","year":"2020","unstructured":"Sch\u00f6ffski P, Blay JY, Ray-Coquard I. Cabozantinib as an emerging treatment for sarcoma. Curr Opin Oncol. 2020;32(4):321\u201331. https:\/\/doi.org\/10.1097\/CCO.0000000000000644.","journal-title":"Curr Opin Oncol"},{"key":"7775_CR74","doi-asserted-by":"publisher","first-page":"1013359","DOI":"10.3389\/fonc.2023.1013359","volume":"13","author":"EDG Fleuren","year":"2023","unstructured":"Fleuren EDG, Vlenterie M, van der Graaf WTA. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and ewing sarcoma. Front Oncol. 2023;13:1013359. https:\/\/doi.org\/10.3389\/fonc.2023.1013359.","journal-title":"Front Oncol"},{"issue":"3","key":"7775_CR75","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","volume":"21","author":"A Italiano","year":"2020","unstructured":"Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werl\u00e9 N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY. Cabozantinib in patients with advanced ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):446\u201355. https:\/\/doi.org\/10.1016\/S1470-2045(19)30825-3.","journal-title":"Lancet Oncol"},{"issue":"14","key":"7775_CR76","doi-asserted-by":"publisher","first-page":"7518","DOI":"10.3390\/ijms22147518","volume":"22","author":"M Tazzari","year":"2021","unstructured":"Tazzari M, Bergamaschi L, De Vita A, Collini P, Barisella M, Bertolotti A, Ibrahim T, Pasquali S, Castelli C, Vallacchi V. Molecular determinants of soft tissue sarcoma immunity: targets for immune intervention. Int J Mol Sci. 2021;22(14):7518. https:\/\/doi.org\/10.3390\/ijms22147518.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7775_CR77","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41523-022-00413-1","volume":"8","author":"DYX Ng","year":"2022","unstructured":"Ng DYX, Li Z, Lee E, Kok JST, Lee JY, Koh J, Ng CC, Lim AH, Liu W, Ng SR, Lim KS, Huang XX, Hong JH, Guan P, Sim Y, Thike AA, Nasir NDM, Li S, Tan PH, Teh BT, Chan JY. Therapeutic and Immunomodulatory potential of pazopanib in malignant phyllodes tumor. NPJ Breast Cancer. 2022;8(1):44. https:\/\/doi.org\/10.1038\/s41523-022-00413-1.","journal-title":"NPJ Breast Cancer"},{"key":"7775_CR78","doi-asserted-by":"publisher","first-page":"755433","DOI":"10.3389\/fonc.2021.755433","volume":"11","author":"F Scirocchi","year":"2021","unstructured":"Scirocchi F, Napoletano C, Pace A, Rahimi Koshkaki H, Di Filippo A, Zizzari IG, Nuti M, Rughetti A. Immunogenic cell death and Immunomodulatory effects of Cabozantinib. Front Oncol. 2021;11:755433. https:\/\/doi.org\/10.3389\/fonc.2021.755433.","journal-title":"Front Oncol"},{"key":"7775_CR79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","volume":"6","author":"L Paoluzzi","year":"2016","unstructured":"Paoluzzi L, Cacavio A, Ghesani M, Karambelkar A, Rapkiewicz A, Weber J, Rosen G. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24. https:\/\/doi.org\/10.1186\/s13569-016-0064-0.","journal-title":"Clin Sarcoma Res"},{"issue":"1","key":"7775_CR80","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41467-024-44875-2","volume":"15","author":"HJ Cho","year":"2024","unstructured":"Cho HJ, Yun KH, Shin SJ, Lee YH, Kim SH, Baek W, Han YD, Kim SK, Ryu HJ, Lee J, Cho I, Go H, Ko J, Jung I, Jeon MK, Rha SY, Kim HS. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial. Nat Commun. 2024;15(1):685. https:\/\/doi.org\/10.1038\/s41467-024-44875-2.","journal-title":"Nat Commun"},{"key":"7775_CR81","doi-asserted-by":"publisher","unstructured":"Tine BAV, Eulo V, Toeniskoetter J, Ruff T, Luo J, Kemp L, Tellez CM, Weiss MC, Hirbe AC, Meyer CF, Elias AD, Diamond M, Hartner LP, Bui N, Ganjoo KN, Maki RG. and Breelyn A. Wilky randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma. JCO. 2023;41:LBA11504-LBA11504. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA11504","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA11504"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07775-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07775-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07775-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:07:05Z","timestamp":1772582825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07775-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7775"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07775-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest related to this study and confirm that the research was conducted independently, without any commercial or financial relationships that could be construed as potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"311"}}